CRDF stock forecast, quote, news & analysis
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential... Show more
Why Cardiff Oncology (CRDF) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- Cardiff Oncology (CRDF) shares declined roughly 27% over the last 30 days, falling from about $1.20 to near $0.88 as of the most recent close.
- The pullback came after a sharp mid-September rally driven by the resolution of the Nerviano Medical Sciences licensing dispute and an analyst upgrade to Buy.
- Over the trailing quarter, the stock is up about 7%, reflecting the net effect of the September rally and the subsequent retreat.
- Financing remains a key overhang as the company works to fund the pivotal CRDF-005 Phase 3 study of its lead candidate, onvansertib.
- Cardiff Oncology is scheduled to report third-quarter results on October 29, 2026.
- For additional context on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated trading systems are approaching this and other tickers.
Cardiff Oncology (CRDF) Company Overview and Market Position
Cardiff Oncology, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapies for cancer. Its lead drug candidate, onvansertib, is an oral and selective Polo-like Kinase 1 (PLK1) inhibitor being developed primarily for RAS-mutated metastatic colorectal cancer (mCRC), an area of significant unmet medical need.
The company is advancing onvansertib toward a pivotal Phase 3 registrational study known as CRDF-005, building on data from its Phase 2 CRDF-004 trial in first-line KRAS- or NRAS-mutated metastatic colorectal cancer. Because Cardiff is a pre-revenue, single-asset biotech, its valuation is tied closely to clinical data readouts, regulatory milestones, and its ability to fund development. Investors follow the stock for its exposure to a validated oncology target and the potential for partnerships or licensing deals, while weighing the risks inherent in late-stage clinical development.
Cardiff Oncology (CRDF) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRDF declined approximately 27%, moving from a close near $1.20 on September 28 to about $0.88 at the most recent close. The decline was not linear; the stock traded near the low $1.20s in late September before steadily weakening through October, with a notable drop into the low $0.80s in the final sessions of the period.
The quarterly picture is more mixed. Measured from a close of roughly $0.82 in late July, the stock is up about 7% over the trailing three months. That gain reflects a strong mid-September move higher—when shares briefly traded above $1.30—followed by a retracement that has largely erased the rally. The result is a stock that remains modestly positive over the quarter but firmly negative over the most recent month.
What Drove CRDF Stock Price in the Last 30 Days
The recent decline largely represents a giveback of gains following a catalyst-driven rally. On September 14, Cardiff Oncology announced a settlement with Nerviano Medical Sciences that amended their 2017 exclusive licensing agreement for onvansertib, resolving outstanding litigation and establishing a revised royalty structure and development milestones tied to the upcoming Phase 3 program. The following day, HC Wainwright upgraded the stock to Buy from Neutral.
That news pushed shares higher, but the momentum faded as investors refocused on the company's fundamentals. As of June 30, 2026, Cardiff reported cash, equivalents, and short-term investments of approximately $34.5 million, and management has stated that additional capital will be required to fund and initiate the CRDF-005 Phase 3 registrational study. The resulting financing overhang has weighed on sentiment, and the approaching third-quarter earnings report scheduled for October 29, 2026, added to near-term caution in a thinly traded, single-asset biotech.
What Drove CRDF Stock Performance Over the Last Quarter
The broader three-month trend has been shaped by the same two competing forces: clinical and legal progress on one side, and funding requirements on the other. During the quarter, Cardiff reported second-quarter results, completed a $10 million registered direct offering in July to extend its cash runway, and ultimately resolved the Nerviano dispute that had introduced uncertainty around its flagship asset.
The September settlement removed a meaningful overhang and, combined with the analyst upgrade, briefly lifted the stock above $1.30. However, because the company remains pre-revenue and will likely need additional capital to reach the pivotal trial, those gains proved difficult to sustain. The quarterly net result is a stock that has round-tripped much of its September advance.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's highest-performing and most relevant automated trading systems. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most pertinent bots are highlighted in this section. These bots differ in strategy, trading timeframe, and performance metrics, giving traders a way to compare quantitative approaches across varying market conditions. For investors looking to complement their own research on tickers such as CRDF with systematic, data-driven signals, the page offers a practical starting point.
CRDF Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. First, Cardiff's third-quarter earnings report, scheduled for October 29, 2026, will provide an updated view on cash balances, operating expenses, and the company's progress toward initiating the CRDF-005 Phase 3 study. Second, any announcement regarding additional financing—whether through an equity offering, partnership, or licensing arrangement—is likely to be a key driver of the share price given the stated capital requirements.
Beyond financing, clinical execution remains central. Updates on the design, timing, and initiation of the pivotal onvansertib trial, as well as any new data presentations, will shape the investment narrative. Regulatory and competitive developments in the mCRC treatment landscape, along with broader risk appetite for small-cap biotech, are additional factors worth tracking. As always with clinical-stage companies, outcomes remain uncertain and dependent on trial results and market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRDF in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where CRDF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRDF's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CRDF turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CRDF moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRDF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (3.498). P/E Ratio (-1.326) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology